Immatics N.V

NASDAQ:IMTX   3:59:51 PM EDT
13.19
-0.05 (-0.38%)
Products

Immatics Presents Data Update On Dose Escalation From Ongoing Actengine Cell Therapy Programs

Published: 03/17/2021 11:54 GMT
Immatics N.V (IMTX) - Immatics Presents Data Update on Dose Escalation From Ongoing Actengine® Cell Therapy Programs.
Immatics NV - Actengine Product Candidates Were Well Tolerated.
All Adverse Events Were Transient and Manageable.
Immatics NV - No Dose-limiting Toxicities Were Observed in Patients Treated With Ima201 and Ima202.
Immatics NV - One Patient Receiving Ima203 at Dose Level 2 Experienced a Dose Limiting Toxicity (dlt) As Defined in the Trial Protocol.